By Dr. Sergey Terushkin, MD, FACS
Florida Surgery & Weight Loss Center
Key Takeaways:
🟢 Most patients lose 8–18 pounds in the first 3 months on semaglutide once an effective dose is reached.
🟢 Semaglutide helps reduce appetite and cravings, supporting steady, medically supervised fat loss.
🟢 Visible before-and-after changes commonly appear by months 2–3.
🟢 Long-term results at 6–12 months often reach 10–20% total body weight loss for many patients.
🟢 Medical supervision improves safety, side effect management, and long-term success.
Additional visual examples and educational content may be available on our Instagram for general informational purposes only.
Most patients lose 5–10% of their body weight in the first 3 months on semaglutide once they reach an effective dose. For many, this equals 8–18+ pounds, depending on starting weight, dose, and lifestyle factors.
As a board-certified bariatric and weight loss surgeon, I’ve seen semaglutide become one of the most widely used and well-studied medications in medical weight loss. For many patients, Ozempic® and Wegovy® provide reliable appetite control and meaningful fat loss when used under proper medical supervision.
In this article, I’ll share what I observe in real clinical practice — including before and after patterns, realistic timelines, and what patients can expect at 3, 6, and 12 months on semaglutide.
Semaglutide is a GLP-1 receptor agonist that works by:
Brand-name versions include:
Semaglutide has one of the largest bodies of clinical evidence in obesity medicine.
When patients ask me what results to expect, I emphasize that individual responses vary. That said, common clinical patterns include:
Semaglutide tends to produce consistent, sustainable weight loss, especially for patients who combine treatment with nutrition and lifestyle support.
Most patients are titrating doses during the first month. I commonly see:
Typical weight loss:
➡️ 3–8 pounds
Some patients feel slow progress early — this is normal during dose escalation.
By month two, many patients reach a dose where effects are more noticeable:
Typical cumulative loss by 2 months:
➡️ 6–14 pounds
By month three, changes are often more noticeable:
Typical cumulative loss by 3 months:
➡️ 8–18+ pounds
➡️ 5–10% of starting body weight
From a medical perspective, semaglutide shows its greatest value over time.
Many patients reach:
➡️ 10–15% total body weight loss
Some patients achieve:
➡️ 15–20%+ total body weight loss
These results can significantly improve:
| Feature | Ozempic® | Wegovy® |
|---|---|---|
| FDA Indication | Type 2 diabetes | Chronic weight management |
| Typical Use | Often off-label for weight loss | FDA-approved for obesity |
| Dosing | Lower max dose | Higher max dose |
| Insurance | Often diabetes-focused | Weight loss coverage varies |
| Weight Loss | Effective | Often greater at higher doses |
From a clinical standpoint, Wegovy® is preferred for obesity treatment when available and covered.
Patients who often respond best:
Medication is a tool — but long-term success still depends on comprehensive care.
Most common side effects I see:
These are usually manageable with:
Using semaglutide without medical oversight increases the risk of:
At Florida Surgery & Weight Loss Center, we monitor:
This approach improves both safety and results.
Semaglutide has helped many patients achieve meaningful, medically significant weight loss. While newer medications like tirzepatide may produce greater early weight loss for some, semaglutide remains a well-established, highly effective option for long-term weight management.
For many patients, semaglutide is a powerful first-line therapy.
Useful links:
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP Trials). New England Journal of Medicine.
Journal articles from the STEP program provide real weight loss timelines and outcomes for semaglutide.
Davies M, et al. Semaglutide 2.4 mg Once Weekly in Adults with Overweight or Obesity: Meta-Analysis.
U.S. FDA. Wegovy® (semaglutide) Prescribing Information.
This article is for educational and informational purposes only and does not replace professional medical advice, diagnosis, or treatment. Information related to semaglutide, including its brand names Ozempic® and Wegovy®, is provided for general educational purposes. Ozempic® and Wegovy® are registered trademarks of their respective owners. Individual results vary. Treatment decisions should always be made in consultation with a qualified healthcare provider based on individual medical needs and health history.
Real people, REAL RESULTS! Check out a few of the many people that we have helped reach their ideal weight goals over the years.
